Targeting cytokines: Reshaping the pancreatic tumor microenvironment

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Pancreatic ductal adenocarcinoma (PDAC) is characterized by a complex tumor microenvironment (TME) with diverse cell types.
• Cytokines, small signaling molecules, are crucial mediators in PDAC, influencing cancer cell proliferation, differentiation, TME modulation, and metastasis.

Purpose of the Study:

• To review the current understanding of cytokines and their multifaceted roles in PDAC.
• To explore the potential of targeting cytokines and cytokine receptors for therapeutic benefit.
• To summarize novel combination therapies involving cytokines with immune checkpoint inhibitors and conventional chemotherapies.

Main Methods:

• Literature review of current research on cytokines in PDAC.
• Analysis of the dual role of cytokines as immunosuppressors and immune enhancers.
• Summary of recent advancements in combination therapies utilizing cytokines.

Main Results:

• Cytokines significantly impact PDAC progression, immune evasion, and therapeutic resistance.
• Targeting cytokine signaling presents a promising strategy for PDAC treatment.
• Combination therapies with cytokines show potential for enhanced efficacy against PDAC growth and metastasis.

Conclusions:

• Cytokines are critical players in PDAC pathogenesis and immune modulation.
• Targeting cytokines, particularly in combination therapies, holds significant promise for improving PDAC treatment outcomes.
• Further translational research and clinical trials are essential to optimize cytokine-based therapeutic strategies.